Literature DB >> 1732004

The mutation Arg (53)----Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor.

S Jorieux1, E A Tuley, C Gaucher, C Mazurier, J E Sadler.   

Abstract

von Willebrand factor (vWF) and factor VIII (FVIII) circulate in plasma as a noncovalently linked protein complex. The FVIII/vWF interaction is required for the stabilization of procoagulant FVIII activity. Recently, we reported a new variant of von Willebrand disease (vWD) tentatively named "Normandy," characterized by plasma vWF that appears to be structurally and functionally normal except that it does not bind FVIII. Three patients from one family were found to be homozygous for a C----T transition at codon 816 converting Arg 53 to Trp in the mature vWF subunit. To firmly establish a causal relationship between this missense mutation and vWD Normandy phenotype, we have characterized the corresponding recombinant mutant vWF(R53W). Expressed in COS-7 cells or CHO cell lines, normal vWF and vWF(R53W) were processed and formed multimers with equal efficiency. However, vWF(R53W) exhibited the same defect in FVIII binding as did plasma vWF from patients with vWD Normandy, confirming that this mutation is responsible for the vWD Normandy phenotype. These results illustrate the importance of Arg 53 of the mature vWF subunit for the binding of FVIII to vWF, and identify an amino acid residue within a disulfide loop not previously known to be involved in this interaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732004

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD.

Authors:  V Siguret; J M Lavergne; G Chérel; C Boyer-Neumann; A S Ribba; B R Bahnak; D Meyer; G Piétu
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

Review 2.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

3.  A conformation-sensitive monoclonal antibody against the A2 domain of von Willebrand factor reduces its proteolysis by ADAMTS13.

Authors:  Jingyu Zhang; Zhenni Ma; Ningzheng Dong; Fang Liu; Jian Su; Yiming Zhao; Fei Shen; Anyou Wang; Changgeng Ruan
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

4.  Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor.

Authors:  Lisbeth Dagil; Kathrin S Troelsen; Gert Bolt; Lars Thim; Bo Wu; Xin Zhao; Edward G D Tuddenham; Thomas E Nielsen; David A Tanner; Johan H Faber; Jens Breinholt; Jakob E Rasmussen; D Flemming Hansen
Journal:  Biophys J       Date:  2019-07-11       Impact factor: 4.033

5.  Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.

Authors:  James R Fuller; Kevin E Knockenhauer; Nina C Leksa; Robert T Peters; Joseph D Batchelor
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.